Evidence map›Paper›PMID 36712696›Full record

ReviewFrontiers in pharmacology2022

Protective effect of natural products in the metabolic-associated kidney diseases

Peng Liu, Yao Chen, Jing Xiao, Wenhui Zhu, Xiaoming Yan, Ming Chen

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Role of Ferroptosis on Lung Epithelial Cells in Disease Progression and Treatment: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Potential candidates from a functional foodFrontiers in endocrinology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Peng LiuShunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China.
Yao ChenDepartment of Medicine, Renal Division, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Jing XiaoDepartment of Medicine, Renal Division, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Wenhui ZhuDepartment of Medicine, Renal Division, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Xiaoming YanDepartment of Medicine, Digestive Division, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Ming ChenDepartment of Medicine, Renal Division, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Heilongjiang Academy of Sciences · CNShunyi Hospital of Beijing Traditional Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome (MS) is a complex group of metabolic disorders syndrome with hypertension, hyperuricemia and disorders of glucose or lipid metabolism. As an important organ involved in metabolism, the kidney is inevitably attacked by various metabolic disorders, leading to abnormalities in kidney structure and function. Recently, an increasing number of studies have shown that mitochondrial dysfunction is actively involved in the development of metabolic-associated kidney diseases. Mitochondrial dysfunction can be used as a potential therapeutic strategy for the treatment of metabolic-associated kidney diseases. Many natural products have been widely used to improve the treatment of metabolic-associated kidney diseases by inhibiting mitochondrial dysfunction. In this paper, by searching several authoritative databases such as PubMed, Web of Science, Wiley Online Library, and Springer Link. We summarize the Natural Products Protect Against Metabolic-Associated Kidney Diseases by Regulating Mitochondrial Dysfunction. In this review, we sought to provide an overview of the mechanisms by which mitochondrial dysfunction impaired metabolic-associated kidney diseases, with particular attention to the role of mitochondrial dysfunction in diabetic nephropathy, gouty nephropathy, hypertensive kidney disease, and obesity-related nephropathy, and then the protective role of natural products in the kidney through inhibition of mitochondrial disorders, thus providing a systematic understanding of the targets of mitochondrial dysfunction in metabolic-associated kidney diseases, and finally a review of promising therapeutic targets and herbal candidates for metabolic-associated kidney diseases through inhibition of mitochondrial dysfunction.

Indexed as

diabetic nephropathygouty nephropathyhypertensive kidney diseasemetabolic-associated kidney diseasesmitochondrial dysfunction (MD)natural productsobesity-related nephropathy

Identifiers

PMID36712696
PMCPMC9877617
OpenAlexW4315640759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.